

**REMARKS**


The specification has been amended to insert reference back to the originally filed U.S. provisional application.

As originally prepared, claim 10 did not comply with the multiple dependent claim styled specified by U.S. law. The amendments submitted herewith to claims 3 and 10 have been made to delete all multiple dependencies.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached page is captions "**Version with markings to show changes made**".

It is respectfully requested that the above amendments be entered before an action on the merits is issued.

Respectfully submitted,

  
Leopold Presser  
Registration No. 19,827

SCULLY, SCOTT, MURPHY & PRESSER  
400 Garden City Plaza  
Garden City, New York 11530  
(516) 742-4343

LP/vjs

**Version with markings to show changes made**

**IN THE CLAIMS:**

Claims 3 and 10 have been amended as follows:

3. (Amended) A method according to claim 1 [or 2] wherein the growth and/or development of cancer is in an animal.

10. (Amended) A method according to claim 1 [any one of claims 1 to 9] wherein the phospholipase inhibitor inhibits secretory PLA<sub>2</sub> which in turn reduces expression of COX2 thereby reducing catalytic conversion of arachidonic acid to prostaglandin.